# Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

> **NCT03881735** · PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Blasts Under 5 Percent of Peripheral Blood White Cells
- Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
- IDH2 Gene Mutation
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Enasidenib
- **PROCEDURE:** Hematopoietic Cell Transplantation

## Key facts

- **NCT ID:** NCT03881735
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-02
- **Primary completion:** 2021-11-19
- **Final completion:** 2022-11-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no accrual
- **Last updated:** 2021-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881735, "Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03881735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*